Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.

The coronavirus-focused stock rises notably on news of yet another partnership with a diagnostics company.

Why Meridian Bioscience Stock Shot Up Nearly 13% Today

CINCINNATI, May  06, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, is pleased to announce its collaboration with QuantuMDx on its newly launched SARS-CoV-2 assay for laboratory use. 

Meridian Bioscience Partners with QuantuMDx on COVID-19 Assay

CINCINNATI, April  30, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.

Meridian Bioscience Announces Closing of Transaction to Acquire Exalenz Bioscience

CINCINNATI, April  27, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today the launch of a novel enzyme master mix (Inhibitor Tolerant 1-step RT-qPCR Mix) that eliminates the need to use an RNA extraction kit prior to running the patient sample through a molecular assay.  By eliminating this step, total assay cost is lower and processing times for COVID-19 samples can be reduced by as much as 30 minutes per test. 

Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply

CINCINNATI, April  14, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19.

Meridian Bioscience offers SARS-CoV-2 antigens for COVID-19 Antibody Tests

CINCINNATI, April  02, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary revenue results for its second quarter of fiscal 2020.

MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH

CINCINNATI, March  16, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection. By utilizing Meridian’s specialized enzyme formulations (Fast RT-qPCR Mix and Lyo-Ready 1-Step RT-qPCR Mix) it is Meridian’s hope that diagnostic companies around the world will be able to develop COVID-19 detection assays with greater sensitivity, faster run-times and formatted for high throughput testing. In order to help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost for the purpose of initial testing and evaluation.  Following the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale in order to meet the global demand.    

Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation

CINCINNATI, March  16, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA® assay. This analyzer and first assay play an important part in their initiative to maintain leadership in the gastrointestinal disease testing market.

Meridian Bioscience Announces FDA-Clearance for New Curian™ Analyzer and the Curian™ HpSA® Assay

CINCINNATI and MODIIN, Israel, Feb.  19, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.  The agreement has been approved unanimously by the boards of directors of both companies.

Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform

Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q1 2020 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 66.67% and -2.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Beats Q1 Earnings Estimates

Flu season normally is a busy time for Meridian Bioscience, but this year just took an unexpected turn.

This Small-Cap Diagnostics Company Just Joined the Coronavirus Battle

CINCINNATI, Jan.  27, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. The outbreak started on the Chinese city of Wuhan, 56 people have already died and more than 2,000 confirmed infected. This new virus has already spread to other parts of mainland China and several other countries and health authorities around the world are taking action to prevent a global epidemic.

Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak

CINCINNATI, Jan.  23, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.

Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications

Meridian Bioscience's (VIVO) CEO Jack Kenny on Q4 2019 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 44.44% and 1.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q4 Earnings and Revenues Surpass Estimates

CINCINNATI, Nov.  06, 2019  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review. This platform and assay are designed to specifically detect Helicobacter pylori antigens in human stool using fluorescent lateral flow technology. Curian™ HpSA is intended to aid in the diagnosis of H. pylori infection and to monitor response during and post-therapy in patients. The addition of this new platform and assay continues to strengthen Meridian’s strategic positioning in the gastrointestinal disease testing market.

Meridian submits Curian™ analyzer and the Curian™ HpSA assay to the FDA

Meridian Bioscience, Inc. (VIVO) CEO John Kenny on Q3 2019 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Meridian Bioscience Stock (VIVO)